Detection of Early Idiopathic Pulmonary Fibrosis
Active, not recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Other: blood samples
- Registration Number
- NCT03457935
- Lead Sponsor
- Temple University
- Brief Summary
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Not provided
Exclusion Criteria
- HIV
- Hepatitis B
- Hepatitis C
- Pregnant or lactating women
inclusion criteria for controls: informed consent >18 years old; no lung diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Non-IPF ILD blood samples non-IPF ILD diagnosis IPF blood samples Naive patients with no IPF treatment Control blood samples no lung diseases
- Primary Outcome Measures
Name Time Method To determine miR200 levels (fold change) in blood samples. Baseline (one time). MicroRNAs (miRs) are noncoding small RNAs, which regulate numerous physiological and pathological processes. miR200 levels will be measured in blood samples collected from control subjects, non-IPF ILD and IPF patients. These samples will be used for identifying biomarkers for IPF.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Temple University
🇺🇸Philadelphia, Pennsylvania, United States